Non-opioid treatment; terms; preferred drug lists; discretion; drug treatment; United States Food and Drug Administration; coverage; non-opioid drugs; reimbursement; effective date.

Removed 'PROPOSED OVERSIGHT COMMITTEE SUBSTITUTE' header and updated to standard 'COMMITTEE SUBSTITUTE' format

Updated page reference numbers from 12857 to 12964

Adjusted line numbers and formatting throughout the document to match House Committee Substitute standards

The entire bill text was replaced with a Committee Substitute version, which includes updated formatting, page numbering, and adoption signatures.

Added committee amendment header, speaker and chair information, and reading clerk signature lines to reflect the bill's progression through the legislative process.

Minor wording adjustments were made to definitions such as changing 'Non-opioid treatment' to 'Non-opioid drug treatment' in one instance for consistency.

Added reference to FDA's 'Approved Drug Products with Therapeutic Equivalence Evaluations' publication when defining non-opioid treatment

Reorganized the bill structure and moved the effective date section to a new Section 2

Updated page headers from 'AS INTRODUCED' to 'ENGROSSED HOUSE' and changed requirement number from 10324 to ENGR. H.B. NO. 1416

Clarified that the non-opioid treatment definition applies to drugs under pharmacy benefit manager contracts